Johnson & Johnson (NYSE:JNJ) updated its FY18 earnings guidance on Tuesday. The company provided EPS guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.10. The company issued revenue guidance of $81.0-81.8 billion, compared to the consensus revenue estimate of $81.18 billion.
Several research firms have commented on JNJ. Zacks Investment Research lowered shares of Johnson & Johnson from a buy rating to a hold rating in a report on Monday. Jefferies Group set a $153.00 target price on shares of Johnson & Johnson and gave the company a buy rating in a report on Friday. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $148.00 to $143.00 and set an equal weight rating on the stock in a report on Tuesday, April 10th. Vetr lowered shares of Johnson & Johnson from a hold rating to a sell rating and set a $124.55 price target on the stock. in a report on Thursday, April 5th. Finally, TheStreet lowered shares of Johnson & Johnson from an a rating to a c+ rating in a report on Monday, March 26th. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $144.03.
NYSE:JNJ opened at $133.15 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. Johnson & Johnson has a one year low of $120.95 and a one year high of $148.32. The company has a market cap of $350,440.66, a P/E ratio of 18.23, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74.
In related news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.22% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $106,000. IHT Wealth Management LLC lifted its position in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $124,000. Financial Gravity Companies Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $143,000. Finally, Delpha Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $166,000. Hedge funds and other institutional investors own 67.23% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.